Home › Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma clinical trials recruiting in the U.S.
191 studies for Head and Neck Squamous Cell Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX49 studies
- Nashville, TN43 studies
- Los Angeles, CA43 studies
- Boston, MA42 studies
- New York City, NY42 studies
- St. Louis, MO32 studies
- Chicago, IL29 studies
- Arlington, VA29 studies
- Philadelphia, PA25 studies
- Pittsburgh, PA23 studies
- Atlanta, GA22 studies
- New Haven, CT22 studies
- Dallas, TX22 studies
- San Antonio, TX22 studies
- Orlando, FL21 studies
- Columbus, OH21 studies
- Cleveland, OH20 studies
- Durham, NC19 studies
- Portland, OR19 studies
- Baldwin Park, CA19 studies
- Queens, NY19 studies
- Baltimore, MD17 studies
- Grand Rapids, MI17 studies
- Tampa, FL16 studies
- Detroit, MI16 studies
- Miami, FL16 studies
- Charleston, SC16 studies
- San Diego, CA16 studies
- Edison, NJ15 studies
- Omaha, NE15 studies
- Rochester, MN14 studies
- San Francisco, CA14 studies
- Oklahoma City, OK14 studies
- Milwaukee, WI13 studies
- Richmond, VA13 studies
- Cincinnati, OH13 studies
- Cedar Rapids, IA13 studies
- Washington, DC13 studies
- Jacksonville, FL12 studies
- Seattle, WA12 studies
By state
- Alabama9 studies
- Arizona19 studies
- Arkansas11 studies
- California75 studies
- Colorado26 studies
- Connecticut25 studies
- Delaware3 studies
- District of Columbia9 studies
- Florida57 studies
- Georgia24 studies
- Idaho4 studies
- Illinois33 studies
- Indiana13 studies
- Iowa15 studies
- Kansas8 studies
- Kentucky17 studies
- Louisiana7 studies
- Maryland22 studies
- Massachusetts44 studies
- Michigan39 studies
- Minnesota25 studies
- Missouri33 studies
- Montana6 studies
- Nebraska17 studies
- Nevada5 studies
- New Hampshire5 studies
- New Jersey27 studies
- New Mexico4 studies
- New York55 studies
- North Carolina30 studies
- North Dakota6 studies
- Ohio46 studies
- Oklahoma15 studies
- Oregon19 studies
- Pennsylvania42 studies
- Rhode Island8 studies
- South Carolina23 studies
- South Dakota9 studies
- Tennessee48 studies
- Texas75 studies
- Utah20 studies
- Vermont4 studies
- Virginia49 studies
- Washington19 studies
- West Virginia3 studies
- Wisconsin15 studies
Recently updated studies
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07741643ABY-029 Head & Neck Phase 1 Trial
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07279116Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07360314Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Recruiting
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07784855Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07667400Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT04671667BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05136196Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06589804Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07741565Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06627270A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07825597Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07783581A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07418034Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06914999High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06992427VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT03556228A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07219212A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06385080A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 3, 2026 · NCT04892173From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.